Total Knee Arthroplasty in Five Days: Universal or Targeted Staphylococcus Decolonization?
A single patient, five days from an elective knee replacement, with a documented MRSA history and a nasal culture that won't return in time to guide the decision either way. The disagreement is whether her own chart already answers the question a pending lab result was supposed to settle.
T.M., a 67-year-old woman, has cared for her husband through six years of progressing dementia, timing her own errands and appointments around his adult day-program schedule with the same discipline she once brought to thirty years of teaching middle-school math. Her right knee, worn down by osteoarthritis on top of longstanding rheumatoid arthritis, has made that caregiving harder each month, and she is five days from the total knee arthroplasty she has been waiting eight months to schedule. Her rheumatoid arthritis is managed on weekly methotrexate, continued through the perioperative period per her rheumatologist's standard practice, but it is still a real second layer of surgical-site-infection risk sitting on top of the joint replacement's own baseline — methotrexate blunts the same neutrophil and lymphocyte response a surgical wound depends on to clear a small bacterial inoculum before it becomes a deep infection. Three years ago she was treated for a MRSA skin abscess on her forearm — resolved, documented, and never re-tested since.
Preoperative nasal MRSA PCR was ordered at her surgical clearance visit, standard practice before joint replacement at this hospital, but the lab has been running five to six days behind on that specific assay, and her surgery is in five. The question the team is actually arguing isn't about her methotrexate or her age — it's whether to decolonize her now, before the result exists, or wait and risk operating with no information at all. REDUCE-MRSA, the trial usually cited for universal decolonization, randomized ICU patients, not elective arthroplasty patients — a different population with a different daily MRSA-acquisition risk than someone arriving from home for a scheduled procedure. Bode and colleagues' trial is the closer match: it screened elective surgical patients directly and decolonized only documented S. aureus carriers, cutting surgical-site infection specifically in that carrier subgroup. Neither trial, read on its own terms, quite answers what to do about a five-day-old nasal swab whose result nobody will see before she's under anesthesia — one was never designed to isolate her situation, the other was designed around a test result she doesn't yet have and, on current timing, will not have before she's on the table.
Preoperative planning, five days out
Her PCR isn't coming back before Thursday, full stop — the lab told us five to six days and we have five. REDUCE-MRSA found that decolonizing everyone, without waiting on a culture result, cut MRSA clinical cultures and bloodstream infection of any pathogen by a wide margin compared to targeted, culture-driven decolonization. I don't want to send her into a knee replacement on methotrexate with an unresolved question hanging over her nose.
You're right that we won't have her result in time — that part isn't in dispute. But REDUCE-MRSA was done in ICU patients — about seventy-four thousand of them across seventy-four adult ICUs in forty-three hospitals — with a daily nosocomial-acquisition risk that has nothing to do with someone walking in from home for a scheduled knee replacement. Bode's trial is the one actually built for her situation: they screened nearly seven thousand admissions with a rapid PCR test, decolonized only the roughly one in five who carried any S. aureus, not just MRSA, and cut S. aureus infection in that group specifically — most sharply for deep surgical-site infection. Applying mupirocin to every elective patient regardless of status is exactly the exposure pattern behind the mupirocin-resistant S. aureus strains our own lab has started flagging this year.
"Don't wait on a culture" is the right instinct in an ICU where infection risk accrues by the hour. It's a different bet in someone who's been colonization-free, as far as we know, for three years.
I don't think this is actually a universal-versus-targeted question for her specifically, whichever way that policy debate should go for the next thousand patients. She has a real, documented MRSA history — that's not a five-day-old pending result, that's her own chart. A positive culture three years ago in a woman who hasn't been re-tested since is enough on its own to treat her presumptively now, independent of whether REDUCE-MRSA's logic should extend to every elective patient who walks through that door.
Decolonize her. Don't let her case decide next month's protocol either direction — that's a different argument with a different evidence base, and it deserves its own review, not a ruling made under her five-day deadline.
Agreed: start mupirocin and chlorhexidine decolonization now, based on T.M.'s own documented MRSA history, without waiting for the pending PCR result that will not return before her surgery date.
Not agreed: whether the unit should move to universal preoperative decolonization for all elective joint-replacement patients going forward, or keep the targeted, screening-driven default and treat cases like hers as individual exceptions. The orthopedic surgeon favors moving toward universal decolonization given the logistics; the infection preventionist wants the question referred to a formal policy review rather than decided by a single deadline-driven case. Flagged for that review, not settled tonight.